Following is a Statement by the National Osteoporosis Foundation on the U.S. Food and Drug Administration’s Approval of Once-a-Month ACTONEL ®
Washington, DC (June 10, 2008)– Osteoporosis is a serious, widespread and growing public health threat, according to the National Osteoporosis Foundation (NOF). NOF welcomes any new FDA approved treatment options, such as Once-a-Month ACTONEL®, that will help patients address this prevalent disease. NOF estimates 10 million Americans age 50 and older have osteoporosis and another 34 million are at risk for the disease.
###
Established in 1984, the National Osteoporosis Foundation is the nation’s leading voluntary health organization solely dedicated to osteoporosis and bone health. Our mission is to prevent osteoporosis, to promote lifelong bone health, to help improve the lives of those affected by osteoporosis and related fractures, and to find a cure. For more information on osteoporosis and bone health, contact NOF online at www.nof.org or by telephone (800) 223-9994.
Back to
the Press Release Index
